Parabilis Medicines is preparing for a planned IPO seeking to raise more than $400 million to fund phase 3 development of its desmoid tumor drug prospect. The filing process is aimed at providing capital to advance clinical timelines that typically require large, sustained spending for late-stage trials. The desmoid program is expected to be the center of the company’s value proposition going into public markets, with projections pointing to potential gross proceeds well above the initial target if demand is strong. For investors, the IPO also serves as a barometer for appetite toward oncology developers in a funding environment that remains selective, particularly when late-stage data and regulatory clarity are still pending. In practical terms, the proceeds would likely determine how quickly Parabilis can scale trial execution, expand site footprints, and manage the cash runway through the completion of the pivotal study.